Skye Bioscience, a San Diego-based biopharmaceutical company, focuses on cannabinoid-based therapeutics for metabolic disorders and inflammation. Its Phase 2 candidates include nimacimab for obesity and SBI-100 OE for glaucoma.
Scott M Rocklage sold 170,449 shares of SKYE on 22 August at $3.42 per share, worth a total of $583K. They now own 1,457,064 SKYE shares, or a 75% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
